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At the end of the 1980s, Switzerland witnessed
a rapid increase in drug related problems. The in-
crease of heroine consumption; the advent of open
drug scenes in several cities; the rapid emergence
of the AIDS epidemic among i.v. drug users and
their degrading social condition had become in-
creasingly visible. In 1991, the Swiss Federal
Council commissioned the Federal Office of Pub-
lic health to implement ProMeDro1 [1], the first
national programme aimed at reducing drug asso-
ciated problems. These measures are based on a
model of 4 pillars (prevention, therapy and reinte-
gration, harm reduction, and repression and con-
trol). Their primary objectives are: to maintain and
improve the state of health and social integration
during the phase of active drug use; to decrease and
hinder the entry into dependence; to increase and
facilitate an exit from dependence (i.e. to decrease
the number of drug users, the main expected out-
come).
This article aims at analysing and synthesising
– a decade later – the epidemiological situation, the
trends in the magnitude and the consequences of
illegal drug use in Switzerland with two objectives:
to broadly explore if the primary objectives of the
programme have been attained2 and to facilitate an
informed discussion among the medical commu-
nity during the debate about the revision of the
Law governing narcotics.
Different issues will be discussed: 
a) The prevalence and trends in the use of various
drugs (such as heroin and /or cocaine, cannabis and
party drugs) in the general population.
b) The magnitude and seriousness of risks and
harm associated mainly with intravenous drug use,
especially those associated with HIV and Hepati-
tis, as well as the evolution of the health (including
access to treatments) and social condition of heav-
ily dependent drug users in Switzerland.
This analysis is part of the evaluation of the
measures the Confederation took in order to re-
duce drug related problems in Switzerland3 [2].
Background and method: As part of the evalua-
tion of the Confederation’s measures to reduce
drug related problems, a review of available data
on drug use and drug related problems in Switzer-
land has been conducted. Source of data included:
population surveys (adults and teenagers), surveys
among drug users, health statistics (drug related
and AIDS related deaths, HIV case reporting, drug
treatments) police statistics (denunciations for
consumption). 
Results: The aims of reducing the number of
dependent hard drug users have been achieved
where heroin is concerned. In particular, there
seems to have been a decrease in the number of
people becoming addicted to this substance. For
all other illegal substances, especially cannabis, the
trend is towards an increased use, as in many
European countries. As regards dependent drug
users, especially injecting drug users, progress has
been made in the area of harm reduction and treat-
ment coverage.
Conclusion: This epidemiological assessment
can be used in the discussions currently engaged
about the revision of the Law governing narcotics
and will be a baseline for future follow up of the
situation.
Key words: drug use; epidemiology; Switzerland 
313Original article S W I S S  M E D  W K LY 2 0 0 4 ; 1 3 4 : 3 1 3 – 3 2 1 ·  w w w. s m w. c h
Peer reviewed article
Summary
Introduction
1 ProMeDro: 
Programme de
mesures de santé
publique de la
Confédération en
vue de réduire les
problèmes de
drogue.
2 Irrespective of the
causality relation-
ship between the
policy of the Con-
federation and the
possible epidemio-
logical changes:
this analysis is only
one part of the
evaluation of the
measures of the
Confederation to
reduce drug related
problems in
Switzerland 
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To estimate the prevalence of drug use (consequently
the number of drug users), different indicators can be used
[3] and combined to gain a global picture of a phenome-
non difficult to measure due to its illegal character. Direct
indicators measure the consumption of drugs as reported
by different types of populations in surveys, and allow
estimating lifetime and current4 prevalence. Indirect indi-
cators do not measure consumption directly, but events
(such as death or legal consequences) related to the preva-
lence of drug use. 
Data presented in this article originated from various
published sources and represent the best available sources
in Switzerland5 until 2000:
a) The cross-sectional surveys including the direct in-
dicators used here are: the Swiss Health Survey (SHS) [4],
the survey on HIV/Aids prevention in Switzerland (EPSS)
[5, 6] the cannabis survey6 [7] the Swiss Multicentric Ado-
lescent Survey on Health (SMASH) [8] among teenagers,
the Health Behaviour in School aged Children (HBSC [9])
and a regularly repeated survey among severely depend-
ent drug users attending needle exchange programmes
(NEP [2, 10]). The main characteristics of the repeated
surveys are summarized in Table 1.
The indirect indicators considered here are: the num-
ber of charges brought for the consumption of illegal
drugs and the number of drug related deaths, both ob-
tained from police statistics [2, 11]; 
b) To estimate the magnitude and seriousness of risks
and harm, social indicators (housing, employment) and
health indicators (reported HIV and Hepatitis prevalence,
intensity and mode of consumption, number of drug users
in treatment) were used. They were obtained from several
treatment statistics: ambulatory [12–17] and residential
[18–23] services, methadone treatments [24], treatments
with medically prescribed heroin [25], HIV/AIDS na-
tional statistics at the FOPH [26, 27] as well as from NEP
surveys [2]. 
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Methods
HBSC* SMASH** SHS*** EPSS**** NEP****
Age category 11–15 16–20 15–74 17–45 all
Population School children Adolescents in schools Households with fixed Households with Dependent drug users 
and apprenticeship telephone fixed telephone visiting needle exchange 
programmes 
N 8700 9000 20000 2800 Variable (around 900)
Sampling Random sampling Stratified cluster Random / random Random / random Systematic recruitment
of classes sampling during one week
Method Self completed Self completed paper Computer assisted CATI Questionnaire partly face 
paper questionnaire questionnaire telephone interview to face, partly self 
(CATI) completed
Response 85.5% classes, Non response rate 64% Refusal rate 12.5% 69%
rate 90% school children 0.3%
Periodicity 4 years 10 years 5 years irregular irregular
1st survey 1978 1992 1992 1987 1993
Last survey 2002 2002 2002 2000 2000
* Conducted by the Swiss Institute of Prevention of Alcoholism
** Conducted by the Institutes for Social and Preventive Medicine of Lausanne and Zurich (1992)
*** Conducted by the Federal Office of Statistics
**** Conducted by the Institute for Social and Preventive Medicine of Lausanne
Table 1
Main characteristics
of periodic surveys
used in this article.
Results
Heroin and cocaine
During the last decade heroin consumption
seems to have stabilized or slightly decreased. The
repeated cross-sectional surveys among the gen-
eral population [2] (see figure 1) showed at the 
end of the 1980s a moderate increase of lifetime
“hard drugs” (heroin and/or cocaine) consumption
among the population aged 17–30 (3.6% in 1987,
4.1% in 1992). From 1992 to 2000 this proportion
has stabilized. Although there is a stabilization of
lifetime “hard drugs” consumption since the mid
1990s untill 2000, the trend over the entire period
has increased, due to a rise of lifetime cocaine con-
sumption: data from the survey SHS [4] shows that
lifetime heroin consumption between 1994 and
1998 followed a slightly decreasing trend while
lifetime cocaine consumption was increasing (see
below and figure 1).
Current consumption of heroin [4] in the pop-
ulation aged 15 to 39 was stable between the years
1993–98 (0.1%). The difference between current
and lifetime prevalence7 may be attributed to ex-
perimentation or consumption over a short period
of time. 
Not only has the consumption of heroin
within the general population diminished but so
did drug injection [2] (figure 1). The proportion of
people having had a drug injection experience8
(lifetime prevalence) remained stable between
1987 and 1995 (0.8% and 1% respectively). Since
4 During the last
twelve months.
5 There is no selec-
tion in the pub-
lished sources.
Other data such as
hospitalisation data
would be useful
but are not avail-
able in Switzerland. 
6 Conducted by the
Swiss Institute of
Prevention of Alco-
holism in 2000
among the general
population aged
15–75.
7 Lifetime prevalence
of consumption of
a drug is the pro-
portion of persons
having ever con-
sumed this drug
8 With any drug.
1995, this proportion decreased from 1% to 0.4%
in 2000. A similar trend is observed among regu-
lar drug users participating in needle exchange
programmes (NEP) [2, 28]. Among them, the
proportion of regular heroin consumers9 has
decreased between 1993 and 2000 (63% and 54%
respectively) and the proportion of “new” drug
injectors (since less than two years) has also
decreased: 30% in 1993, 14% in 1996 and 7% in
2000. 
As stated, indirect indicators follow a similar
trend to that of direct indicators. Since the mid
1990s charges brought for heroine consumption
and drug related deaths have decreased [12, 29,
29]. Statistics gathered from entries into treatment
and surveys undertaken on users of needle ex-
change programmes (NEP), either show an in-
crease or a stabilisation of the average age of heroin
users and a decrease of the proportion of current
users (less than two years of use). This suggests
there is a decrease of heroin dependent users
(fewer newcomers) and an increase of patients re-
tained in treatment.
Estimates on the number of regular heroin
users have been made based on the triangulation
of different direct and indirect indicators, such as
data gathered from cross-sectional surveys, drug
related deaths, denunciations for heroine con-
sumption and treatments. In 1990–1993 the num-
ber was estimated at around 30,000 and in 1997
this number was estimated at 28,000 [30, 31]. 
Lifetime cocaine consumption among the
population aged 15–39 increased from 2.7% to
3.3% between 1993 and 1998 [4] (figure 1). Cur-
rent consumption in the same population and over
the same period remained stable at 0.4% [4]. The
difference between lifetime and current consump-
tion suggests that a part of cocaine consumption is
experimental. 
Surveys among users of needle exchange pro-
grammes (NEP) [2] show that the proportion of
cocaine or cocktail (heroin and cocaine simultane-
ously) users has increased from 1993 to 1996 (31%
and 37% respectively) but decreased in 2000 to
27% and 25% respectively. The average number
of drug injections per week also decreased (18.9 in
1993 and 13.7 in 2000). Charges brought for co-
caine use have been on the decline since the end of
the 1990s (10,515 in 1997 to 8206 in 2001). These
two different trends suggest that cocaine use as a
recreational substance may have increased in the
general population while consumption decreased
among the heavily dependent drug users.
Cannabis
Trends and the different data relating to
cannabis consumption are very clear. Cannabis
consumption has increased sharply since the be-
ginning of the 1990s among the general popula-
tion; this increase is clearly perceptible among
young people aged fifteen. The average age of
teenagers consuming cannabis has decreased (av-
erage age of first consumption decreased from 16.5
in 1992/93 to 15.8 in 1997/1998 [32]) while the
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Figure 1 
Evolution of heroine
and/or cocaine life-
time consumption
among the Swiss
population
(1987–2000) [2].
9 Several times 
a week.
quantities consumed have increased. Since 1990,
surveys among pupils aged fifteen (HBSC) (see fig-
ure 2) showed a high increase of lifetime cannabis
consumption, which has more than tripled be-
tween 1990 (8.5%) and 1998 (30.8%) [4]. The last
available data collected in 2002 among pupils
15–16 years old showed a continuation in the in-
crease in lifetime prevalence of cannabis con-
sumption: 49.9% among boys and 39% among
girls [33].
Through an observation of lifetime consump-
tion in the population aged 17 to 30 (EPSS) [2, 6],
one sees more precisely the recent increase. This
increase is of lower amplitude as compared to con-
sumers aged 15. It is only during the mid 1990s
that the proportion of lifetime cannabis use in this
age group grew from 22.1% in 1994 to 37.8% in
2001. The variation between these two curves
(adults vs. pupils) is mainly due to a generation ef-
fect, since the recent increase of lifetime cannabis
consumption among the 17–30 years old seems to
be attributable to the increase in the youngest.
This observation is confirmed by a recent survey
realized in 2000 detailing cannabis consumption
[7]: lifetime prevalence of cannabis consumption is
lower in older ages (44% of those aged 15–19; 59%
for those aged 20–24; 35% for those aged 25–44;
15% for those aged 45–59).
Concerning the frequency of cannabis con-
sumption, one observes that two thirds of the
cannabis consumption among teenagers declared
in 1998, was repeated use [4]. The survey realized
in 2000 [7] among the general population confirms
this result, 6.5% of those aged 15–19 consume
cannabis every day and an other 5% at least once
a week. This survey also confirms the inverse rela-
tionship between current consumption of cannabis
and age. The proportion of current cannabis con-
sumption is 24% for the 15–19 year olds and 28%
for the 20–24 year olds. This is in sharp contrast
to the 10% found between 25–44, and 4% for
45–59. One can once again talk of both a genera-
tion and an age effect: the previous generation,
when aged 15 consumed less cannabis, hence fewer
lifetime consumers and a cessation of consumption
with age may have been recorded. 
Indirect indicators confirm the observed
trends; charges brought relating to cannabis use
continue to increase, particularly during the last 10
years, in spite of a more liberal environment re-
garding cannabis use in some parts of Switzerland
[11, 29]. This increasing upward trend may in part
be explained by the fact that certain cantons have
a more repressive policy, as compared to others;
this is the case in French speaking Switzerland,
where we see a higher number of consumers.
Party Drugs, designer drugs (ecstasy, 
amphetamines, hallucinogens …)
Data concerning these drugs are of bad qual-
ity as: the classification of substances from one sur-
vey to another differs; new substances and denom-
inations of these substances are constantly evolv-
ing. It is therefore very difficult to know and iden-
tify the evolution of these drugs within society.
The cross-sectional surveys among the population
aged 15–39 show that lifetime consumption of
stimulants and hallucinogens ranged from 1 to 4%
in 1997/98 [4].
Two surveys were undertaken among young
people attending rave parties in Switzerland [34,
35]. These surveys concerned a restricted popula-
tion mixing with the techno scene but did however
allow identification of consumer characteristics
and modes of consumption. These surveys do not
inform us of the prevalence of consumption. The
results of these different surveys are: the level of
consumption of different substances is high and
the people who frequent the techno scene are poly-
users. Half (52%) of that population had consumed
ecstasy and one third (33%) of ravers when asked
were consuming this substance during the survey.
Almost all (94%) of ecstasy users had tried other
illegal drugs during the last twelve months; 64%
of ecstasy users had already consumed cocaine,
38% LSD, 14% heroin and 90% cannabis. Seven-
teen percent of the same population used ecstasy
once a week or more. As a general rule, ecstasy
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Evolution of soft
drugs/cannabis life-
time consumption
among population
aged 17–30 and
pupils aged 15 in
Switzerland,
1987–2000 [2].
users are socially integrated and use the drug recre-
ationally. The average age of first consumption of
ecstasy is 18 years old.
Health problems related to heavy drug use
When evaluating the state of health of con-
sumers and the seriousness of consumption, one
must place a greater emphasis on the more de-
pendent consumers of heroin and/or cocaine. The
data presented below were gathered from: surveys
among users of needle exchange programmes, sta-
tistics relating to entries into treatment, data from
the HIV notification system and police statistics. 
The state of health of dependent drug con-
sumers is generally improving. The number of
newly reported HIV cases among i.v. drug users
has greatly decreased between 1989 (approxi-
mately 400 reported cases) and 2001, and seems to
have stabilised (approximately 50 reported cases
[36]). In the surveys among NEP attendees and in
statistics of those undergoing treatment, the re-
ported HIV prevalence has remained relatively
stable, or has decreased slightly (between 5% and
11% during past years according to the source of
data). The prevalence of HIV has remained rela-
tively low compared to that of Hepatitis B and C,
which are very high particularly among those vis-
iting needle exchange programmes. In 2000, 59%
of needle exchange programme clients reported
having been tested positive once for Hepatitis C
and 40% for Hepatitis B [2]. In the statistics relat-
ing to entries into residential treatment, between
1997 and 2000, the same indicator shows a preva-
lence of approximately 40% for Hepatitis C and
between 22% and 28% for Hepatitis B [19–22]. 
Surveys undertaken in Switzerland among
users of needle exchange programmes (NEP) [2]
enabled us to evaluate the risks of contamination
associated with both HIV and Hepatitis amongst
drug users. The average number of drug injections
per week has decreased (18 in 1996, 14 in 2000),
but important regional differences still exist. How-
ever, a small recent increased risk of HIV trans-
mission among drug injectors was observed: the
proportion of users who have shared syringes dur-
ing the last 6 months increased from 9% in 1994
to 12% in 2000. Other forms of risky behaviours
linked to intravenous drug use such as the sharing
of spoons, filter and water have decreased since
1996, but remain high when considering the risks
associated with the development of Hepatitis C
(sharing of spoon during the last 6 months: 68%in
1996 and 51% in 2000; sharing of filter: 46% in
1996 and 38% in 2000). This could help explain
the relatively high rate of Hepatitis C. Risk be-
haviour during sexual relations has remained sta-
ble over time. The rate of condom use with occa-
sional partners is comparable to that found among
the general population (in 2000, 72% used a con-
dom consistently). However, the rate of consistent
condom use with the stable partner (in 2000 only
29% had always used a condom with a stable sex-
ual partner) is still unsatisfactory given the fact that
HIV seroprevalence among drug users is high and
surveys show that drug users often have non-drug
taking sexual partners.
Drug related deaths have decreased between
1994 and 2001, stabilising at 200 deaths per year
since 1998 [11, 29]. The number of HIV related
deaths has also decreased over the same period,
primarily due to the arrival of antiretroviral treat-
ments (figure 3).
The number of people in treatment has con-
tinued to increase. Since the end of the 1980s un-
till the beginning of the 1990s the number of
methadone substitution treatments has consider-
ably increased (2000 treatments in 1987 and
14,000 in 1994). Until 1996 the situation remained
stable, probably due to the development of med-
ical prescription of heroine. Since 1997 the num-
ber of methadone substitution treatments again in-
creased (in 2000, 18,393 registered treatments) [1,
24]. Figure 4 graphs the evolution of the number
of methadone treatments in the different cantons
between 1993 and 2000. When reporting the num-
ber of those undergoing treatment among the pop-
ulation aged 20 to 64, the cantons of BS, GE and
NE retained the highest rate: respectively 8.86, 6.6
and 6.51 per thousand people. Other types of treat-
ments have also increased during the last decade,
currently approximately 1100 drug users are
treated with medically prescribed heroin [25] and
1000 places are currently assigned for treatments
in specialised residential structures [37].
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Social situation of dependent drug users
The social situation of dependent drug con-
sumers is drawn from employment, income and
housing information collected from the statistics
of entry into various treatments or in surveys con-
ducted in needle exchange programmes (i.e. these
data are related to heavily dependent drug users,
generally injecting drugs). 
Housing conditions have slightly improved,
with a decrease of homeless drug consumers (12%
in 1993 and 10% in 2000 in needle exchange pro-
grammes; 10.1% in 1995 and 4.6% in 2001 in the
statistics of entry to residential treatment). The
number of people benefiting from social welfare /
social aid has increased, as well as the number of
those benefiting from social insurance, such as
invalidity insurance and unemployment insurance
(in needle exchange programmes beneficiaries of
social insurance were 22% in 1994, 27% in 1996,
29% in 2000 [2]). On the other hand the propor-
tion of people declaring illegal income (primarily
through deals) has decreased. Access to employ-
ment has not improved over the last years, with
59% of drug users in needle exchange programmes
and 42% of entrants into residential treatment
being unemployed. Dependent drug users may
have a greater accessibility to the social security
system, hence, they experience fewer social prob-
lems, but they certainly still have problems at-
tempting to take positive steps towards social
reinsertion, particularly with regards to the work
environment.
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Discussion
Data allowing an estimation of the evolution
of the prevalence and of the varying modes of con-
sumption of different substances are primarily
drawn from surveys conducted among the general
population, particularly among the youth, young
adults and consumers themselves. The precision of
these estimates is subject to several biases. Decla-
ration bias may occur: the fact that the substances
under scrutiny are illegal may induce under or over
declaration by the user due respectively to volun-
tary caution or provocation. Moreover, declaration
bias may change over time. For example part of the
increase in cannabis use may reflect an increasing
number of persons admitting cannabis use (change
in the social norm). Another source of error may
originate from the small samples (large confidence
intervals) and scarcity of the phenomenon (heroin
and cocaine consumed). It is also likely that a part
of severely dependent drug users having no private
home are not represented in the surveys. However,
these biases affect mainly the magnitude of esti-
mates, and their impact on the reliability of trends
is limited [1, 38] because data collection conditions
do not change from one survey to another. More-
over, the triangulation of data collected from reg-
ular statistics (such as deaths, treatment and police
statistics) and from other sources allows us to val-
idate the main evolutions. International compari-
son offers another way of validation and contextu-
alisation of trends.
A stabilisation or a decrease in heroin use and
drug injection is currently observed in the general
population and among regular drug users. Euro-
pean countries [38] have the same difficulties as
Switzerland in estimating the evolution of heroine
use. Data collection is not standardised and na-
tional data are not directly comparable. Never-
theless, similarly to that of Switzerland’s, heroin
consumption in the UK and France seems to have
stabilised or decreased. 
On the other hand the consumption of cocaine
seems to have increased slightly, especially for
recreational use. This increase of cocaine use is
also observed in other European countries [38]. In
France between 1995 and 1999, lifetime preva-
lence of cocaine use among the male population
aged 18–44 increased from 2.8% to 3.7%. In the
UK, lifetime prevalence of cocaine use among the
population aged 16–29 increased from 6% to 10%
between 1998 and 2000. 
Difficulties in obtaining data for the use of
party drugs is also evident in other parts of Europe,
though certain trends do seem to be emerging. An
increase in the use of recreational drugs (party
drugs) occurred in the early 1990s, particularly in
the United Kingdom, Germany and Spain (preva-
lence of lifetime use among 18–59 year-olds: 9%,
3% and 2% respectively). In these countries, the
situation seems to have stabilised around these fig-
ures in recent years. Elsewhere, we are seeing an
increase in use, particularly among young people
(18–25 year-olds). The general population surveys
reveal a prevalence of lifetime use in most Euro-
pean countries of between 1% and 4% (3% in 
the case of France in 1998, 1% in Finland and
Sweden) [38–40]. A European study performed 
in techno circles in Berlin, Amsterdam, Vienna,
Prague, Madrid and Zurich revealed high levels of
use of legal and illegal substances among young
people in 1996. Two years later, however, a de-
crease in drug use (in terms of frequency, volume,
number of substances) was observed in the same
groups. This was ascribed mainly to bad experi-
ences (or fewer positive experiences) with the sub-
stances concerned, incompatibility between drug
use and lifestyle changes, and other social factors
[41]. These different tendencies observed in Eu-
rope may suggest that the diffusion of synthetic
drugs is not infinite and that saturation may occur.
Regarding cannabis, various studies showed an
impressive increase in the frequency and quantity
of consumption, essentially in the younger popu-
lation, with an earlier onset of use. Cannabis use
has also increased in most European countries
since the beginning of the 1990s [38]. Lifetime
consumption of cannabis among the general pop-
ulation is highest in Switzerland, Denmark and the
UK. Among teenagers aged fifteen, an increase in
lifetime consumption is also observed in most Eu-
ropean countries. 
The definition of a risky consumption of
cannabis remains tricky: at the collective level, the
meaning of the use of psychoactive substances un-
dergoes timely and cultural variations; at the indi-
vidual level, the patterns of consumption fluctuate
during adolescence in the sense of an improvement
or worsening of the situation. It is thus difficult to
decide at which point cannabis use becomes wor-
risome [42–44]. The most serious – although rare
– negative consequences of cannabis use usually
discussed are an increase in the occurrence of se-
vere mental health problems in youth (such as de-
pression or schizophrenia), as well as an increase
in traffic accidents under the influence of cannabis.
In the literature there is evidence of a link between
cannabis consumption in adolescents and occur-
rence of psychiatric disease [45–48]. However,
“whether the use of cannabis triggers the onset of
schizophrenia or depression in otherwise vulnera-
ble people or whether it actually causes these con-
ditions in non-predisposed people is not yet re-
solved” [49].
The state of health of dependent drug users
over the last 10 years has improved. The number
of HIV cases as well as the number of drug and
AIDS related deaths have diminished. The fre-
quency of drug injection and the use of condoms
have remained stable. The proportion of needle
exchange programme users who have shared sy-
ringes during the last 6 months slightly re-in-
creased in the last years (12%), however this pro-
portion is still one of the lowest recorded in Euro-
pean needle exchange programmes [38]. Other
forms of risk behaviour (sharing spoon, cotton,
water), though still high are lowering. Prevalence
of Hepatitis C infection remains high, hence the
importance of the need to develop prevention
among high-risk users and maintain Hepatitis test-
ing and Hepatitis B vaccination. 
The treatment of drug consumers is also in
progress, with the numbers requiring treatment
continually increasing. In total, more than 50% of
dependent drug consumers undertake treatment,
which in comparison to other European countries
remains one of the highest rates [38].
The social situation of the regular consumer is
generally improving slightly, with a decrease in the
number of homeless and of people declaring ille-
gal sources of income, and an increase in the pro-
portion of people benefiting from social welfare.
However, social reinsertion particularly the devel-
opment of accessibility to employment must im-
prove.
This synthesis of available data on the drug sit-
uation in Switzerland and the analysis of current
trends was part of the assessment of the drug pol-
icy of the Confederation. However, this type of
analysis alone is not sufficient to discuss the effec-
tiveness of this policy and any causality interpre-
tation performed only on this basis should be
avoided. The Confederation’s objectives of stabil-
isation or reduction in the use of drugs have been
attained for heroin, but not for the other illegal
drugs which are on the increase as in many Euro-
pean countries. Notable progress has been made
with regards to risk reduction in the health and so-
cial domains, as well as in treatment coverage. This
epidemiological assessment can be used in the dis-
cussions currently engaged about the revision of
the Law governing narcotics and will be a baseline
for future follow up of the situation, especially for
the assessment of the effects of the new Law.
We wish to thank J. Fournier for the translation of
this article.
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